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Abstract. This paper details research towards the optimal placement of a novel 
robotic device for the detection and treatment of prostate cancer, via biopsy and 
brachytherapy respectively. A methodology for analysis of available data in order 
to determine geographical areas with relatively high prevalence of prostate can-
cer and low access to treatment is proposed. Areas in the South of the UK with 
high values of these indices are highlighted.  The development of single and mul-
tiple criteria optimization models based on the new metric in order to optimally 
locate a small number of future prototype treatment devices is discussed. Discus-
sions, conclusions and avenues for future research are given.  
Keywords: Healthcare Technologies, Cancer detection and treatment, Optimi-
zation. 
1 Introduction 
This study focuses on finding the optimal locations for a small number of prototype 
robotic devices in the South of the United Kingdom for the detection and treatment of 
prostate cancer. This problem is considered as part of a project for the development of 
the robotic device, funded by the European Union 2-Seas Interreg scheme under the 
CoBra (Co-operative Brachytherapy) [1] project.     
The remainder of this paper is divided into three sections which describe the data 
analysis (Section 2) and and model formulation and solution (Sections 3), and conclu-
sions and suggestions for future work (Section 4. 
2 Data analysis 
2.1 Identification of the Prostate cancer Occurrence Hotspot 
Two distinct quantities can be used to assess the prevalence of prostate cancer, namely 
prostate cancer incidence, and prostate cancer mortality rate. Prostate cancer incidence 
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represent the number of patients (per year) who are diagnosed with prostate cancer. The 
diagnosis methods used are not consistent throughout the UK, and the efficacy of dif-
ferent methods are different; this renders incidence rate unsuitable for comparing pros-
tate cancer prevalence in different areas of the UK. Therefore, mortality rate is a better 
measure for this purpose [2], and is used in this analysis. The only risk factors of pros-
tate cancer currently known are age and ethnicity.  Deprivation does not seem to affect 
the risk of prostate cancer [2, 3]. A quantitative breakdown of the risk is available, for 
age groups with 5 year increments [3], which has been used in this study. The risk is 
very low before the age of 50, after which the mortality rate monotonically increases 
with age.  
To exclude the effect of different age profiles in different populations, prostate can-
cer mortality rates are commonly expressed as Age Standard (AS) rates, which reveal 
the real differences between populations which can be attributed to factors other than 
age.  
Ethnicity is the other factor relevant to the risk of prostate cancer. Compared to white 
males, Age-Standard (AS) prostate cancer mortality rate is significantly lower in Asian 
men, and significantly higher in Black males. For this reason, the ethnic demographics 
of the population may have to be taken into account in order to obtain a reliable estimate 
of prostate cancer prevalence in different areas. However, a study of prostate cancer 
mortality rates in different areas of Britain (analyzed at ward1 level) revealed a flat 
distribution map; i.e. the AS mortality rate is quite uniform in the UK. This means that 
the differences in ethnical demographics of different areas within the UK can be ignored 
in estimating prostate cancer prevalence, and age demographics alone are sufficient for 
that purpose. Therefore, age has been used as the sole estimating factor in this study, as 
follows: 
1. The geographic area of study (the southern part of England, in the 2 seas zone) was 
first broken down to the level of postcode district (i.e. PO2). 
2. The age demographics of the population in each postcode district were then obtained 
from the Office of National Statistics [4]. The data contains the number of male 
residents of an area, within each age range. Each age range spans over five years 
(e.g. 50-54 years old).   
3. The Age-Standard risk rate of prostate cancer for different age ranges [3] was used 
together with age demographics of each postcode district to produce an estimate. To 
do this, the number of the male population within each age range was multiplied by 
the prostate cancer rate corresponding to that age range, as follows: 
∑ 𝑀𝑖 . 𝑃𝑖
𝑛
𝑖=1   
where Mi and Pi are the male population and the Prostate cancer rate for the i’th age 
group, respectively, and n is the number of age groups.  
This was done for all age ranges, and the sum of all products represents the estimated 
rate of prostate cancer for the given postcode district.  
4. The procedure was executed for all postcode district, to produce a map of prostate 
cancer dispersion in the area studied.  
                                                          
1 A ward is a district level geographic division in The UK.  
3 
The map of the area studied is shown in Fig. 1, together with the centroids of the 
postcode districts in the area of study. The centroids are significant because the distance 
from each postcode district (to a given treatment center) was measured from its cen-
troid. The prostate cancer prevalence map developed in this study is represented in a 
color intensity graph in Fig. 2.  
 
 
Fig. 1. The Southern parts of England within the 2 Seas area (left), and the centroids of the 
postcode districts within the 2seas area in the UK (right) 
 
Fig. 2. The color-intensity graph of the estimated prostate cancer rate (patient/year) in each 
postcode district within the 2 seas zone in the UK 
2.2 Identification of the Prostate Cancer Treatment Dry-Spots 
The term dry here refers to a relative lack of access to treatment facilities, which has 
been measured by the distance from the considered area to the nearest prostate cancer 
treatment facilities. The current version of the analysis is based on the linear (Euclid-
ean) distance rather than road distance, which is one of the limitations of this work. Fig. 
3 shows the location of the treatment centers for prostate cancer.  
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Fig. 3. The location of the treatment centers (red dots), and the centroids of the postcode districts 
within the 2seas area in the UK (blue dots) 
3 A strategy to find the optimal location 
 The method used to solve the problem is as follwos: 
1. For each of the potential hosting locations (the treatment centers shown in Fig. 3), a 
total travel time distance was defined, as follows: 
a. For each of the postcode districts, the number of the patients in that district was 
multiplied by the distance to the given treatment center. The resultant value was 
calculated and saved for all of the postcode districts. 
b.  The sum of the above-mentioned value for all of the postcode districts was saved 
as the total travel distance for the given treatment center.  
2. The total travel distance, explained above, was calculated for all of the treatment 
center.  
3. The treatment center with the smallest value of the total travel distance was identified 
as the optimal location.  
The optimization goal is to minimize the travel distance for all of the patients who may 
be potential receivers of the treatment provided by the new device. The result shows 
that the optimal location is the treatment center in Surrey, shown in .Fig. 3. 
4 Discussion and Conclusion  
In this paper, we have developed a methodology towards the development of an opti-
mized facility location modelling that includes geographical areas with relatively high 
prevalence of prostate cancer against access to treatment centers. We have focused our 
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application on the South of the UK.  A detailed mapping has identified age as the dom-
inant factor for the analysis. The development and combination of measures for inci-
dence and ease of access allows the identification of priority postcode areas. These are 
useful from a policy perspective as they show the areas most in need of enhanced pro-
vision, and from a modelling perspective as they allow effective measurement criteria 
for the development of single and multiple criteria optimization models.  
  The suggested single and multiple criteria facility location model offers a promising 
platform for future modelling developments. These relate on a specific level to the Eu-
ropean Union project in which the next generation prostate cancer detection and treat-
ment devices are being developed. On a general level, the mapping and proposed opti-
mization models in this paper can be seen as the basis as a wider methodology to iden-
tify priority geographical areas for placement of medical resources to detect and treat 
disease, particularly in the case of a relatively small amount of resources and a large 
potential treatment population.  
  Further modelling developments involve the development of multiple criteria facility 
location models for the allocation of the small number of robotic devices. These could 
relate to the improvement of access for specific target postcodes with (i) poor access 
(dryness), (ii) high incidence levels (hotness) or (iii) combination of the both as detailed 
by the methodology develop in this paper. Specific targets could be developed for these 
priority postcodes and for the general population with respect to access time, travel 
distance and associated patient costs. Trade-off with respect to priority versus general 
access and the cost of locating multiple devices could be explored via a multi-objective 
weight sensitivity analysis. Given the target-based and geographical nature of this prob-
lem, extended network goal programming [10] is a viable modelling methodology.   
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